Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00640250 · ClinicalTrials.gov registry record · Phase 2
Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response
A Phase 2 study, sponsored by Allerderm.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT00640250 is a Phase 2 study that has completed, run by Allerderm. The registered enrollment target is 48 participants.
The verdict
NCT00640250, a Phase 2 study, has completed, sponsored by Allerderm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
We propose a prospective, multi-center, double-blind, randomized study comparing the diagnostic performance (primary) and safety (secondary) of 3 concentrations of Disperse blue 106 and 4 concentrations of Bronopol in 40 adult subjects (20 subjects per allergen) with a clinical history of contact dermatitis and a positive patch test (current or previous) to the corresponding reference petrolatum allergen ("sensitives").
Interventions
- BIOLOGICAL T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00640250
The ClinicalTrials.gov registry entry for NCT00640250 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allerderm, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens is the first listed.
NCT00640250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00640250 about?
NCT00640250 is a clinical study titled "Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response". We propose a prospective, multi-center, double-blind, randomized study comparing the diagnostic performance (primary) and safety (secondary) of 3 concentrations of Disperse blue 106 and 4 concentrations of Bronopol in 40 adult subjects (20 subjects per allergen) with a clinical history of contact de...
What is the current status of trial NCT00640250?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2008-04. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00640250?
The interventions under investigation include: T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens (BIOLOGICAL).
Who is sponsoring clinical trial NCT00640250?
This trial is sponsored by Allerderm, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.